Back

FDA Approves Wilserdly Combination for Breast Cancer

Giredestrant, sold by Genentech under the name Wilserdly, received FDA approval on November 16, 2026, for use alongside everolimus. According to the agency, the approval covers adults whose locally advanced or metastatic breast cancer is ER-positive, HER2-negative and carries an ESR1 mutation, subject to testing and prior-treatment requirements.

Roche describes giredestrant as an oral estrogen-receptor antagonist and selective estrogen-receptor degrader. Its intended mechanism combines preventing estrogen from binding with inducing the receptor protein’s breakdown.

According to the FDA, eligibility requires an ESR1 mutation identified through an FDA-authorized test. The cancer must have returned during or following endocrine-based adjuvant treatment, or progressed after at least one endocrine-based regimen for metastatic disease. The agency also authorized the companion diagnostic FoundationOne Liquid CDx to identify patients with ESR1 mutations for the combination.

The evidence reviewed by the FDA came from evERA, an open-label, randomized study conducted across multiple centers. It enrolled 373 adults with locally advanced or metastatic disease that was ER-positive and HER2-negative; tumors in 207 participants carried ESR1 mutations. All participants had previously received both endocrine therapy and a CDK4/6 inhibitor. Mutation testing used circulating tumor DNA obtained from blood plasma, with analysis restricted to specified ESR1 ligand-binding-domain mutations.

Everolimus was included in both trial groups. One group received giredestrant, while the comparison group received physician-selected exemestane, fulvestrant or tamoxifen. Among participants with ESR1-mutated tumors, the FDA reported median progression-free survival of 10 months for the giredestrant combination, compared with 5.5 months for the comparison treatment. This measure tracks the interval before cancer progression or death.

For that subgroup, the progression-or-death hazard ratio was 0.38, with a 95% confidence interval of 0.27–0.54; the difference was statistically significant. Objective response rates were 27% for the giredestrant group and 14% for the comparison group. However, according to the FDA’s summary, overall-survival data remained immature at that analysis, and the findings did not establish an overall-survival benefit.

Genentech’s prescribing information specifies a daily oral giredestrant dose of 30 mg alongside everolimus, continued until progression of the disease or toxicity becomes unacceptable. It also specifies a GnRH agonist for women who are premenopausal or perimenopausal and for men, excluding men following bilateral orchiectomy. The same accompanying treatment and exception applied in evERA.

The prescribing information identifies a potential for Wilserdly to reduce heart rate and cause fetal harm. Frequently reported reactions or laboratory abnormalities with the combination include stomatitis, diarrhea, fatigue, and alterations in liver enzymes and blood-cell counts.

Separately, STAT reported Roche’s statement that giredestrant could become its highest-selling product. That remains a company forecast rather than an established sales result.

* This article is based on publicly available information at the time of writing.